Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Ykl-40 Genetic Polymorphisms And The Risk Of Liver Disease Progression In Patients With Advanced Fibrosis Due To Chronic Hepatitis C, Herbert L. Bonkovsky
Ykl-40 Genetic Polymorphisms And The Risk Of Liver Disease Progression In Patients With Advanced Fibrosis Due To Chronic Hepatitis C, Herbert L. Bonkovsky
UCHC Articles - Research
Abstract
Background/Aims
The aim of this study was to explore the association of a functional YKL-40 promoter polymorphism (rs4950928) with baseline disease stage, response to antiviral therapy, and risk of liver disease progression in a group of patients with chronic hepatitis C (CHC).
Methods
YKL-40 promoter polymorphisms were determined in 456 HALT-C Trial patients with bridging fibrosis or cirrhosis entering a prerandomization lead-in peginterferon/ribavirin 24-week treatment phase and in 462 patients followed for a mean of 3.8 years after randomization to maintenance peginterferon or observation.
RESULTS
Mean patient age was 49.5 years, 70.4% were male, and 71.2% were Caucasian. The …
Serum Fibrosis Markers Are Associated With Liver Disease Progression In Non-Responder Patients With Chronic Hepatitis C, Herbert L. Bonkovsky
Serum Fibrosis Markers Are Associated With Liver Disease Progression In Non-Responder Patients With Chronic Hepatitis C, Herbert L. Bonkovsky
UCHC Articles - Research
Abstract
OBJECTIVES
The aim of this study was to explore the association of serum fibrosis marker levels with the risk of clinical and histological disease progression in a large cohort of patients with chronic hepatitis C (CHC)
DESIGN/SETTING
462 prior non-responders to peginterferon and ribavirin enrolled in the randomized phase of the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial had baseline and annual serum samples tested for hyaluronic acid (HA), n-terminal peptide of procollagen type 3, tissue inhibitor of matrix metalloproteinase-1, and YKL-40.
OUTCOME MEASURES
All patients underwent a pretreatment liver biopsy and follow-up biopsies at years 2 …
Prognostic Value Of Ishak Fibrosis Stage: Findings From The Halt-C Trial, Herbert L. Bonkovsky
Prognostic Value Of Ishak Fibrosis Stage: Findings From The Halt-C Trial, Herbert L. Bonkovsky
UCHC Articles - Research
Background and Aims
Studies of the prognostic value of Ishak fibrosis stage are lacking. We utilized multi-year follow-up of the Hepatitis C Antiviral Long Term Treatment Against Cirrhosis (HALT-C) Trial to determine whether individual Ishak fibrosis stages predicted clinical outcomes in patients with chronic hepatitis C.
Methods
Baseline liver biopsies from 1,050 patients with compensated chronic hepatitis C who had failed combination peginterferon and ribavirin were reviewed by a panel of expert hepatopathologists. Fibrosis was staged with the Ishak scale (ranging from 0=no fibrosis to 6=cirrhosis). Biopsy fragmentation and length as well as number of portal tracts were recorded. We …